Concepedia

Nicholas Squittieri

NS

Statistics

Publications

8

Citations

323

H-Index

8

Active since

2019

Affiliations

Sun Pharma (United States)(Current)

Sun Chemical (United States)

Royal North Shore Hospital

The University of Sydney

The University of Texas MD Anderson Cancer Center

Nicholas Squittieri is an author at Sun Pharma (United States) specializing in oncology, basal cell carcinoma, and molecular oncology.

Publications per year

2019–2023

8

Publications

8

Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study

Reinhard Dummer, Alexander D. Guminksi, Ralf Gutzmer et al. · British Journal of Dermatology · 2019 · 193 citations · Full text

, , +16

Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis

Ralf Gutzmer, Carmen Loquai, Caroline Robert et al. · Dermatology and Therapy · 2021 · 25 citations · Full text

, , +16

<p>Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial</p>

John T. Lear, Axel Hauschild, Eggert Stockfleth et al. · Clinical Cosmetic and Investigational Dermatology · 2020 · 23 citations · Full text

, , +17

Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis

Ralf Gutzmer, Caroline Robert, Carmen Loquai et al. · BMC Cancer · 2021 · 22 citations · Full text

, , +15

Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial

Karl D. Lewis, Reinhard Dummer, Aaron S. Farberg et al. · Dermatology and Therapy · 2021 · 20 citations · Full text

, , +17

1–5 of 8